SCHEMBL1474978

SCHEMBL1474978

O=C(NCc1ccccc1)Nc1cc(-c2ccco2)on1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.70
NPC1 O15118 6/20 0.70
SMN1; SMN2 Q16637 5/20 0.70
RAB9A P51151 5/20 0.70
PTPN7 P35236 2/20 0.57
SCD5 Q86SK9 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
HTT P42858 3/20 0.56
MAPT P10636 3/20 0.56
MAPK1 P28482 2/20 0.56
KDM4E B2RXH2 2/20 0.54
PKM P14618 1/20 0.54
EPHX2 P34913 1/20 0.50
TSHR P16473 1/20 0.50
SCD O00767 3/20 0.49
HSD17B10 Q99714 1/20 0.48
HPGD P15428 3/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474947 0.90 ALDH1A1 (0.57) ALDH1A1NPC1SMN1; SMN2RAB9APTPN7
SCHEMBL1475156 0.87 KMT2A (0.72) ALDH1A1NPC1SMN1; SMN2RAB9ASCD5
SCHEMBL1473772 0.84 SMN1; SMN2 (0.55) ALDH1A1NPC1SMN1; SMN2RAB9APTPN7
SCHEMBL1475653 0.82 NPC1 (1.00) ALDH1A1NPC1SMN1; SMN2RAB9ASCD5
SCHEMBL1475763 0.80 SMN1; SMN2 (0.60) ALDH1A1NPC1SMN1; SMN2RAB9ASCD5
SCHEMBL15190045 0.78 ALDH1A1 (0.70) ALDH1A1NPC1SMN1; SMN2RAB9APTPN7
SCHEMBL1474434 0.78 HTT (0.59) SMN1; SMN2RAB9AKMT2AHTTEPHX2
SCHEMBL1475165 0.75 ALDH1A1 (0.62) ALDH1A1NPC1SMN1; SMN2RAB9ASCD5
SCHEMBL1475058 0.75 RAB9A (0.71) ALDH1A1NPC1SMN1; SMN2RAB9AMEN1
SCHEMBL1475720 0.75 NPC1 (0.80) ALDH1A1NPC1SMN1; SMN2RAB9ASCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 ALDH1A1 706/4885NPC1 2242/4885SMN1; SMN2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.